case_images: PMC10731593_01
case_images: A, Pretreatment image of case 1 showing multiple areas of nonscarring alopecia after failing upadacitinib. B, Posttreatment image of case 1 showing marked improvement after 6 months.
case_images: gr1.jpg
case_images: PMC10731593_01_gr1.jpg
case_images: fig1
case_images: A 70-year-old female presented to our dermatology clinic with a SALT baseline of 53 and disease duration of more than 10 years (Fig 1, A). The patient was prescribed 4 mg of baricitinib daily for a 6 month duration in which she achieved SALT 20 (Fig 1, B).
case_images: PMC10731593_02
case_images: A, Pretreatment image of case 2 while on tofacitinib 11 mg extended release. B, Posttreatment image of case 2 showing slight improvement after 5 months of baricitinib 4 mg every day. C, Posttreatment image of case 2 demonstrating further improvement after 9 months of baricitinib 4 mg every day.
case_images: gr2.jpg
case_images: PMC10731593_02_gr2.jpg
case_images: fig2
case_images: She was treated with tofacitinib 11 mg extended-release which resulted in her eyebrows and eyelashes growing back but no scalp-hair growth after 1.5 years of treatment (Fig 2, A). While the patient's temporal and occipital scalp fully grew, her vertex was still bald (Fig 2, B and C).
case_images: PMC10731593_03
case_images: A, Pretreatment image of case 3 after failing upadacitinib. B, Posttreatment image of case 3 showing marked improvement after 8 months of baricitinib 4 mg every day.
case_images: gr3.jpg
case_images: PMC10731593_03_gr3.jpg
case_images: fig3
case_images: While her AD completely cleared, she achieved just partial hair regrowth after 6 months of therapy and subsequently relapsed to a SALT 100 (Fig 3, A). Patient was subsequently started on baricitinib 4 mg daily and by 8 months had achieved SALT 5 (Fig 3, B).